Managing weight loss medications like GLP-1 receptor agonists requires navigating insurance formularies and treatment effectiveness, as highlighted by recent changes at CVS Caremark/United Healthcare removing Zepbound from their coverage in August 2025. Many patients experience shifts in their weight loss regimen due to such changes. Zepbound, known for its high effectiveness, helped the author achieve remarkable weight loss, but it was ultimately removed from the formulary. When switched to Wegovy, the medication proved ineffective, underscoring the importance of individual responses to different GLP-1 therapies. This case emphasizes the critical role of prior authorization processes. Even with a normal BMI, providing thorough documentation like InBody scans can justify continued treatment access, as insurers increasingly require evidence of ongoing medical necessity. The author’s proactive communication with healthcare providers and the insurance company resulted in an eight-month approval for Mounjaro, a GLP-1 receptor agonist sometimes covered for weight loss if Wegovy is ineffective. Weight loss journeys often involve multiple approaches, including surgery such as gastric sleeve procedures complemented by medications like Mounjaro and Zepbound. Starting with Mounjaro before surgery and returning to it after formulary challenges provides a full-circle approach to sustaining weight management. For those navigating insurance restrictions, alternatives include paying out-of-pocket through programs like LillyDirect to access Zepbound at discounted prices. Patients are encouraged to discuss medication effectiveness openly with their healthcare providers to adjust treatment plans accordingly. This realistic, user-generated content sheds light on the complexities and persistence needed in long-term weight loss management using GLP-1 medications amid evolving insurance landscapes.